Unveiling the role of PGCCs in tumor recurrence and therapeutic resistance: Hidden architects of cancer’s comeback
Pathology - Research and Practice · 2026
DOI: 10.1016/j.prp.2025.156347 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pathology - Research and Practice, 2026. Verfasst von Mokhtar Rejili und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, College of Sciences, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh 11623, Saudi Arabia. Hauptthemen laut MEDLINE: Neoplasm Recurrence, Local, Neoplasms, Drug Resistance, Neoplasm, Giant Cells. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 153 Literaturangaben. Gefördert von: Imam Mohammed Ibn Saud Islamic University, Imam Mohammed Ibn Saud Islamic University Deanship of Scientific Research.
Abstract (Originalsprache)
Polyploid Giant Cancer Cell (PGCCs) have emerged as pivotal players in cancer biology, contributing to tumor heterogeneity, recurrence, metastasis, and resistance to conventional therapies. Characterized by their enlarged size, aberrant nuclear morphology, and stem-like properties, PGCCs arise in response to environmental stressors such as chemotherapy, radiation, and hypoxia. These cells enter a dormant state, evade treatment, and later become reactivated to generate tumor-repopulating progeny through depolyploidization and asymmetric division (neosis). Daughter cells derived from PGCCs exhibit enhanced invasive capabilities, epithelial-to-mesenchymal transition (EMT), and metabolic adaptability, rendering PGCCs formidable obstacles in cancer management. Their unique biology involves complex molecular mechanisms including endoreplication, cell fusion, and autophagy, which facilitate survival and proliferation under stress conditions. Elucidating PGCC formation and behavior opens new avenues for targeted therapeutic strategies, encompassing immunomodulation, metabolic interference, and differentiation-based approaches. This paradigm shift in cancer research underscores the urgency for innovative diagnostic tools and personalized treatment modalities to effectively counter PGCC-driven malignancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biology, College of Sciences, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh 11623, Saudi Arabia.
- Department of Comparative Biosciences, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran. Electronic address: faridhashemi360@gmail.com.
Förderung
- Imam Mohammed Ibn Saud Islamic University
- Imam Mohammed Ibn Saud Islamic University Deanship of Scientific Research
Zitieren
APA
Rejili, M., & Hashemi, F. (2026). Unveiling the role of PGCCs in tumor recurrence and therapeutic resistance: Hidden architects of cancer’s comeback. Pathology - Research and Practice. https://doi.org/10.1016/j.prp.2025.156347
Vancouver
Rejili M, Hashemi F. Unveiling the role of PGCCs in tumor recurrence and therapeutic resistance: Hidden architects of cancer’s comeback. Pathology - Research and Practice. 2026. doi:10.1016/j.prp.2025.156347
BibTeX
@article{Rejili2026,
author = {Rejili, Mokhtar and Hashemi, Farid},
title = {Unveiling the role of PGCCs in tumor recurrence and therapeutic resistance: Hidden architects of cancer’s comeback},
journal = {Pathology - Research and Practice},
year = {2026},
doi = {10.1016/j.prp.2025.156347}
}
EUVIMED